Trials Sponsors Conditions Drugs Pricing

Conditions

Attention Deficit Hyperactivity Disorder

Keywords

ADHDtryptophanexecutive function

Outcome Measures

Primary Outcomes (3)

Serum level of Indolepropionic acid [IPA]
tryptophan metabolite
1 year
Serum level of indoleacetic acid [IAA]
tryptophan metabolite
1 year
Serum level of kynurenic acid [KYNA]
tryptophan metabolite
1 year

Secondary Outcomes (8)

ADHD Rating Scale-IV
1 year
Swanson, Nolan, and Pelham IV scale
1 year
Achenbach Child Behavior Checklist
1 year
Clinical Global Impressions-ADHD-Severity
1 year
Social Adjustment Inventory for Children and Adolescents
1 year
+3 more secondary outcomes

Study Arms (2)

Patients with ADHD

drug-naive patients with ADHD, aged 7-18 year old

Healthy Controls

drug-naive healthy controls, aged 7-18 year old

Eligibility Criteria

Age7 Years - 18 Years

Sexall

Healthy VolunteersYes

Age GroupsChild (0-17), Adult (18-64)

Sampling MethodProbability Sample

Study Population

120 drug-naïve patients with ADHD, aged 7 to 18 years, will be enrolled. Another 120 healthy participants with matched age and sex will be enrolled in the control group.

You may qualify if:

Patients with ADHD are eligible to be included in this study only if they meet all of the following criteria:

Sponsors & Collaborators

National Taiwan University Hospital
Otherlead

Study Sites (1)

National Taiwan University Hospital

Taipei, 110, Taiwan

RECRUITING

Chi-Yung Shang, MDPHDCONTACT02-23123456 ext. 66965 cyshang@ntu.edu.tw

Biospecimen

Retention: SAMPLES WITHOUT DNA

plasma

MeSH Terms

Conditions

Attention Deficit Disorder with Hyperactivity

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior DisordersNeurodevelopmental DisordersMental Disorders

Study Officials

Chi-Yung Shang, MDPHD
Dept of Psychiatry, National Taiwan University Hospital
PRINCIPAL INVESTIGATOR

Central Study Contacts

Chi-Yung Shang

CONTACT

02-23123456 cyshang@ntu.edu.tw

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: CROSS SECTIONAL
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

March 28, 2019

First Posted

April 3, 2019

Study Start

April 1, 2019

Actual (reported)

Primary Completion

March 31, 2020

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Metabolic Pathway of Tryptophan and Executive Dysfunction in Children With Attention Deficit Hyperactivity Disorder

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (3)

Secondary Outcomes (8)

Study Arms (2)

Patients with ADHD

Healthy Controls

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (3)

Secondary Outcomes (8)

Study Arms (2)

Patients with ADHD

Healthy Controls

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations